-
Aoudjhane M et al.
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT).
Leukemia 2005;19:2304-2312.
-
Archimbaud E et al.
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of etoposide, mitoxantrone, and cytarabine-86-trial.
J Clin Oncol 1995;13:11-18.
-
Aversa F et al.
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
N Engl J Med 1998;339:1186-1193.
-
Bassan R et al.
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Haematologica 1998;83:422-427.
-
Biggs JC et al.
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy.
Blood 1992;4:1090-1093.
-
Bosi A et al.
Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation.
J Clin Oncol 2001;19:3675-3684.
-
Breems DA, Löwenberg B.
Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.
Br J Haematol 2005a;130:825-833.
-
Breems DA et al.
Prognostic index for adult patients with acute myeloid leukemia in first relapse.
J Clin Oncol 2005b;23:1969-1978.
-
Choi SJ et al.
Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
Leukemia 2004;18:1789-1797.
-
Cook G et al.
The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Biol Blood Marrow Transplant 2006;12:293-300.
-
Cornelissen JJ, Löwenberg B.
Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia.
In: Löwenberg B, Licht JD, Tallman MS, Cornelissen JJ.
Acute myeloid leukemia, 151-155.
Hematology Am Soc Hematol Educ Program, 2005.
-
Craddock C et al.
Biology and management of relapsed acute myeloid leukaemia.
Br J Haematol 2005;129:18-34.
-
De Botton S et al.
Autologous or allogeneic stem-cell transplantation of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group.
J Clin Oncol 2005;23:120-126.
-
Eapen M et al.
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
Bone Marrow Transplant 2004;34:721-727.
-
Estey EH.
Treatment of relapsed and refractory acute myeloid leukemia.
Leukemia 2000;14:476-479.
-
Estey E et al.
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.
Blood 1996;88:756.
-
Faderl S et al.
The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog.
Cancer 2005a;103:1985-1995.
-
Faderl S et al.
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005b;105:940-947.
-
Ferrara F, Palmieri S, Mele G.
Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
Haematologica 2004;89:998-1008.
-
Fung HC et al.
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
Biol Blood Marrow Transplant 2003;9:766-771.
-
Gale RE et al.
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukaemia, from the UK MRC AML10 and 12 trials.
Blood 2005;106:3658-3665.
-
Giles F et al.
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
Br J Haematol 2006;134:58-60.
-
Grigg AP et al.
Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia.
Br J Haematol 1999;107:409-418.
-
Grimwade D et al.
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties.
Blood 1998;92:2322-2333.
-
Hänel M et al.
Mito-FLAG as salvage therapy for relapsed and refractory acute myeloid leukemia.
Onkologie 2001;24:356-360.
-
Hiddemann W et al.
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Leukemia 1990;4:184-188.
-
Hosing C et al.
Disease Burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
Bone Marrow Transplant 2005;36:157-162.
-
Jackson GH.
Use of fludarabine in the treatment of acute myeloid leukemia.
Hematol J 2004;5(Suppl 1):62-67.
-
Johny A et al.
Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
Biol Blood Marrow Transplant 2006;12:480-489.
-
Kantarjian H et al.
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood 2003;102:2379-2386.
-
Kern W et al.
Superiority of high-dose over intermediate-dose cytosine-arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Leukemia 1998;12:1049-1055.
-
Kern W et al.
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Leukemia 2000;14:226-231.
-
Kern W et al.
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Leukemia 2002;16:2084-2091.
-
Kishi K et al.
Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes.
Bone Marrow Transplant 1997;19:461-466.
-
Kornblau SM et al.
CECA - cyclophosphamide, etoposide, carboplatin and cytosine arabinoside - a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Leuk Lymphoma 1998;28:371-375.
-
Larson RA et al.
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Cancer 2005;104:1442-1452.
-
Lazarus HM et al.
Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center of International Blood and Marrow Transplant Research.
Br J Haematol 2006;132:755-769.
-
Lee JH et al.
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory and early relapsed acute myelogenous leukemia.
Leuk Res 2006;30:204-210.
-
Lee S et al.
Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia.
Leukemia 2000;14:1345-1348.
-
Leoni F et al.
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Haematologica 2002;87:485-489.
-
Leopold LH, Willemze R.
The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature.
Leuk Lymphoma 2002;43:1715-1727.
-
Levine JE et al.
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplant.
J Clin Oncol 2002;20:405-412.
-
Liu Yin JA et al.
Comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
Br J Haematol 2001;113:713-726.
-
Michallet M et al.
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM).
Bone Marrow Transplant 2000;26:1157-1163.
-
Milligan DW et al.
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.
Blood 2006;107:4614-4622.
-
O’Donnell MR.
The role of autologous and allogeneic ("Full" and "Mini") stem cell transplantation in AML, 104-109.
In: Stone RM, O’Donnell MR, Sekeres MA.
Acute myeloid leukemia.
Hematology Am Soc Hematol Educ Program, 2004.
-
Ohno R et al.
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia.
Blood 1994;83:2086-2092.
-
Platzbecker U et al.
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Leukemia 2006;20:707-714.
-
Porter DL.
Donor leukocyte infusions in acute myelogenous leukemia.
Leukemia 2003;17:1035-1037.
-
Revesz D et al.
Salvage by timed sequential chemotherapy in primary resistent acute myeloid leukemia: analysis of prognostic factors.
Ann Hematol 2003;82:684-690.
-
Ringden O et al.
The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed.
Bone Marrow Transplant 2000;25:1053-1058.
-
Schmid C et al.
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Blood 2006;108:1092-1099.
-
Sierra J et al.
Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemia burden, donor HLA-matching, and marrow cell dose.
Blood 1997;89:4226-4235.
-
Sievers EL et al.
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Blood 1999;93:3678-3684.
-
Slovak ML et al.
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study.
Blood 2000;96:4075-4083.
-
Soignet SL et al.
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
J Clin Oncol 2001;19:3852-3860.
-
Song KW, Lipton J.
Is it approbiate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
Bone Marrow Transplant 2005;36:183-191.
-
Stelljes M et al.
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Blood 2005;106:3314-3321.
-
Stone RM.
AML: Current landscape and future directions.
In: Stone RM, O’Donnell MR, Sekeres MA.
Acute myeloid leukemia, 98-103.
Hematology Am Soc Hematol Educ Program, 2004.
-
Takeshita A et al.
Efficacy of gemtuzumab ocogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Leukemia 2005;19:1306-1311.
-
Tallman MS.
New strategies for the treatment of acute myeloid leukemia including antibodies and novel agents.
In: Löwenberg B, Licht JD, Tallman MS, Cornelissen JJ.
Acute myeloid leukemia, 143-150.
Hematology Am Soc Hematol Educ Program, 2005.
-
Tallman MS, Gilliland DG, Rowe JM.
Drug therapy for acute myeloid leukemia.
Blood 2005;106:1154-1163.
-
Tavernier E et al.
Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Leuk Res 2003;27:205-214.
-
Thomas X et al.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Leukemia 1999;13:1214-1220.
-
Thomas X et al.
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Leuk Lymphoma 2005;46:1007-1016.
-
Thomas X et al.
Impact of salvage therapy according to prognostic factors on the outcome of refractory or relapsed acute myeloid leukaemia.
Haema 2006;9:127-135.
-
Tsimberidou AM et al.
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
Br J Haematol 2005;132:398-409.
-
Vogler WR et al.
A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
Leukemia 1994;8:1847-1853.
-
Wong R et al.
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Biol Blood Marrow Transplant 2005;11:108-114.
-
Xu WL et al.
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Leuk Res 2006;30:407-413.
Bildatlas Hämatologie
Druckversion
ISSN: 2193-6021
Zum Seitenanfang